Compare ClearPoint Neuro Inc (CLPT) vs Newegg Commerce Inc (NEGG) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

NEGG trades at $13.87, down 1.98% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $4.88 million for 2025, though revenue improved to $1.44 billion. Recent news highlights AI shopping initiatives and the FantasTech sale, indicating ongoing business development efforts. Cash flow from operations remains negative at -$26.97 million, but financing activities provided a net cash inflow of $8.91 million.

The outlook is mixed; a single analyst rates NEGG a buy, and profitability may recover by 2026. However, persistent operating losses, weak cash generation, and high debt-to-asset ratios pose significant risks. Investors should weigh potential e-commerce growth against fundamental weaknesses and market volatility.